Cathie Wood’s ARK Invest ETFs (exchange-traded funds) revealed several key portfolio moves for Friday, October 31, 2025, ...

Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce ...

Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

Love her or roll your eyes, Cathie Wood’s bets are virtually impossible for investors to miss. With clear theses and gutsy ...

Biopharma has finally begun catching up with the overall stock market, as shares of the top three biopharma exchange traded funds (ETFs) jumped well into double digits over the past six months.

Fintel reports that on October 17, 2025, B of A Securities maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...

HC Wainwright reiterated their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a research report released on Tuesday,Benzinga reports. HC Wainwright currently has a $80.00 ...

Trexquant Investment LP bought a new position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) during the 1st quarter, according to the company in its most recent filing with the SEC.